newsfilter
← Latest News
PR Newswire·

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

INO
  • INOVIO Pharmaceuticals, Inc. & Akeso, Inc. entered a clinical trial collaboration to evaluate INO-5412 combined with cadonilimab for glioblastoma (GBM) treatment.
  • The study will occur within the Phase 2 adaptive INSIGhT trial platform sponsored by Dana-Farber Cancer Institute.
  • INO-5412 consists of the DNA immunotherapy components INO-5401 & INO-9012, which stimulate immune responses against tumor antigens.
  • Cadonilimab is a first-in-class PD-1/CTLA-4 bispecific antibody currently approved in China for gastric cancer, cervical cancer, & other indications.
  • Dosing for the combination therapy trial is expected to commence in the second half of 2026.
  • The partnership aims to leverage additional checkpoint inhibition via CTLA-4 binding to potentially enhance survival outcomes in GBM patients.
  • The INSIGhT trial utilizes a shared control arm to efficiently test multiple investigational therapies simultaneously for newly diagnosed GBM.
  • INOVIO & Akeso will supply therapeutic products for the study while investigative sponsors oversee daily clinical operations.
  • Previous Phase 2 data for INO-5401 combined with a PD-1 inhibitor showed robust immune responses potentially correlating with enhanced survival in GBM.
  • Cadonilimab is currently involved in over 11 Phase 3/registration trials globally, including international studies for gastric cancer & liver cancer.